Redeye comments on the TO6B outcome. With underwriting commitments, the TO6B was subscribed at 100%,...
- We expect 22% organic growth in Q4 and EBIT up 35% y-o-y - 2024e-25e EBIT down 6% as FX shaves 2% ...
Suominen’s earnings recovery continues, but the pace seems to be still somewhat slower than we previ...
Redeye updates its view and outlook on Nanologica following the company’s year-end report and announ...
Redeye comments on Freemelt ahead of its Q4 results (due 20 Feb).
Redeye continues to be positive to Bredband2 following a solid Q4 report, where a higher-than-expect...
Redeye comments on the official launch of MOB-015 under the name Terclara in Sweden.
Redeye reinforces its positive view of CombinedX following a strong Q4 report, with profitability be...
Redeye has made minor estimate changes ahead of the Smart Eye year-end report due in two weeks on Fe...
Mesdopetam EOP2 FDA meeting on 20 Feb, feedback 30 days later Pirepemat Ph 2b full enrolment in Q3'2...
Redeye’s first take on the Q4 report this morning. Cellavision presented a markedly stronger report ...
CapMan reported Q4 EBIT of -4.8m, clearly below Refinitiv consensus at EUR 6m.
Förvaltningsresultat ökade med 25% på årsbasis och substansvärdet uppgår till 207 kronor.
Redeye thinks that Lagercrantz yet again showed resiliency with strong margins and cash flow despite...
Small miss on underlying PTP in Q4 Higher non-recurring items than expected Fair value range down to...
Board recommends shareholders to reject bid Q4 better than it looked at first glance 13x '24e EV/EBI...
Redeye comments on Better Collective’s updated financial targets where it narrows its EBITDA-margin ...
Q4 NOI -2% vs ABGSCe Earnings capacity IFPM -3% vs ABGSC 2024e Higher DPS and reiterate acquisition ...
Redeye ger en kort kommentar om försäljningssiffrorna för Leqembi under Q4 2023, som var lägre än vä...
Q4e: 8% org. top line growth on tough comps Earnings growth remains very strong, adj.